Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8TAC2
UPID:
JOS2_HUMAN
Alternative names:
Josephin domain-containing protein 2
Alternative UPACC:
Q8TAC2; M0QX25
Background:
Josephin-2, also known as Josephin domain-containing protein 2, plays a crucial role in cellular processes through its ability to cleave 'Lys-63'-linked poly-ubiquitin chains, and to a lesser extent 'Lys-48'-linked poly-ubiquitin chains. This specificity suggests a unique function in ubiquitin-mediated signaling pathways.
Therapeutic significance:
Understanding the role of Josephin-2 could open doors to potential therapeutic strategies. Its activity in modulating ubiquitin chains hints at its importance in cellular regulation and disease mechanisms.